Sur­rozen re­loads with $50M for fi­nal dash to the clin­ic, shines some light on lead Wnt-mod­u­lat­ing can­di­dates

Two rounds to­talling $83 mil­lion have pro­pelled Sur­rozen through pre­clin­i­cal proof-of-con­cept, cul­mi­nat­ing in two an­ti­body can­di­dates mod­u­lat­ing the Wnt path­way for tis­sue re­gen­er­a­tion. Now, the …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER